IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
Zacks News
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
ABIOMED's (ABMD) international Impella revenues improve in Q3.
Stryker (SYK) Q4 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Stryker's (SYK) fourth-quarter earnings reflect strong segmental performance.
CONMED (CNMD) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Despite weak segmental performance in fourth quarter, CONMED (CNMD) showed strength and resilience in amid a tough operating environment.
Hologic (HOLX) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in first-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust performances in TMTT business in Q4.
Varian (VAR) Q1 Earnings Beat Estimates, Revenues Miss Mark
by Zacks Equity Research
Varian's (VAR) receipt of 13 Ethos orders in fiscal Q1 raises investors' optimism on the stock.
What's in Store for IDEXX Laboratories (IDXX) in Q4 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) fourth-quarter top line is likely to have benefited from strength in CAG and LPD businesses.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic's (HOLX) CE-Marked Fluent System Launched in Europe
by Zacks Equity Research
Hologic (HOLX) aims to optimize, simplify and streamline hysteroscopic workflow with the latest European launch of its fluid management system.
Here's Why You Should Retain AmerisourceBergen (ABC) Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.
Intuitive Surgical (ISRG) Q4 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results reflect improvement in procedure volume.
Here's Why You Should Retain AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP. Intense competition remains a woe.
Why You Should Retain Pacific Biosciences (PACB) Stock Now
by Zacks Equity Research
Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.
ESG Stocks to Gather Speed Under Biden's Leadership: 5 Picks
by Sreoshi Bera
Biden's administration plans to address climate change and take ESG initiatives. This call for investing in Shopify (SHOP), Magna International (MGA), IDEXX Lab (IDXX), Facebook (FB) and PayPal (PYPL).
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) due to a slew of regulatory approvals and buyouts.
Omnicell (OMCL) Reports Encouraging 2020 Preliminary Results
by Zacks Equity Research
Per the preliminary announcement, Omnicell (OMCL) projects 2020 total revenues to surpass its previous guidance.
Cardiovascular Systems' (CSII) OAS Gets CE Mark for Use in Europe
by Zacks Equity Research
Cardiovascular Systems (CSII) aims to expand treatment options in Europe for patients suffering from severely calcified coronary artery disease following the receipt of regulatory clearance.
Haemonetics (HAE) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Haemonetics (HAE) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.
Quest Diagnostics (DGX) COVID-19 Test Sales Solid, Volume Dull
by Zacks Equity Research
Quest Diagnostics (DGX) notes strong signs of the healthcare system returning to pre-pandemic levels with base testing volume gradually improving.
Intersect ENT's (XENT) Q4 Preliminary Revenues Disappointing
by Zacks Equity Research
Per the preliminary announcement, Intersect ENT (XENT) projects Q4 revenues to decline from the year-ago quarter's reported figure.
Thermo Fisher (TMO) Expands in Viral Vector With Henogen Buyout
by Zacks Equity Research
The addition of Henogen's manufacturing capabilities in Europe complement Thermo Fisher's (TMO) four development and manufacturing sites in North America.
NEOGEN's (NEOG) New Test to Aid in Detecting Cancer-Causing Toxin
by Zacks Equity Research
NEOGEN's (NEOG) latest test is expected to simplify the process of milk testing as well as detecting lower levels of the carcinogenic metabolite Aflatoxin M1.
Masimo (MASI) Reports Encouraging 2020 Preliminary Results
by Zacks Equity Research
Per the preliminary announcement, Masimo (MASI) projects 2020 product revenues to improve.
Integra (IART) Preliminary Q4 Reported Sales Show Recovery
by Zacks Equity Research
Integra's (IART) sales improvement in the fourth quarter is likely to have been boosted by on-going business recovery.
Exact Sciences (EXAS) Posts Solid Preliminary Q4 Testing Revenues
by Zacks Equity Research
Exact Sciences' (EXAS) strength in Screening revenue along with a robust COVID-19 testing arm are likely to have boosted the top line significantly.